

**FACSIMILE TRANSMITTAL SHEET**

**BRISTOL-MYERS SQUIBB COMPANY**  
Patent Department  
P. O. Box 5100  
5 Research Parkway  
Wallingford, CT 06492-7660  
**TELECOPIER NO.: 203-677-6900**

**FAX RECEIVED**

AUG 20 2003

GROUP 1600

  
**OFFICIAL**

**TO:** Examiner Amy E. Pulliam  
PTO Art Unit 1615  
fax: 703-305-3592

**FROM:** Shah Makujina  
Bristol-Myers Squibb Company  
fax: 203-677-6900

**TOTAL NUMBER OF PAGES INCLUDING THIS ONE: 30**

*If this fax is imperfectly received, please contact (203) 677-6877 immediately.*

**DATE:** August 19, 2003

**OFFICIAL**  
**09/973,226 (CT2545ACIP)**

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to 703-305-3592 at the Patent and Trademark Office on the date shown below.

Shah R. Makujina

Type or print name

Signature

8/19/03

Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***In re* Application of: Kothari and Desai

Art Unit: 1615

Application No.: 09/973,226

Examiner: A. Pulliam

Filed: October 9, 2001

For: FLASH-MELT ORAL DOSAGE FORMULATION

MAIL STOP: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §1.111**

This Reply and Amendment is a timely response to a first Office Action dated June 12, 2003 having a three-month shortened statutory period for response expiring September 12, 2003. In Examiner's first Office Action dated June 12, 2003, all of Applicants' pending claims (1-48) were rejected. In the instant response, Applicants have canceled claims 1, 3, 5 and 6 and amended claim 2. Applicants respectfully request reconsideration of the above-entitled application in light of the following amendments and remarks.